Pfizer, Inc. · NYSE:PFE
Pfizer — Merger or Acquisition (February 2015)
9 slides from Pfizer's merger presentation, Feb 5, 2015
Slide 1: Acquisition of Hospira
Acquisition of Hospira February 5, 2015
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Our discussions during this conference call will include forward-looking statements about, among other things, Pfizer’s planned acquisition of Hospira, including its potential benefits, anticipated synergies, accretion, and growth, the co
Slide 3: Aligns with Pfizer's Core Priorities and Key Focus Areas for Global Established Pharma
Aligns with Pfizer’s Core Priorities and Key Focus Areas for Global Established Pharma Global Established Pharma Pfizer’s Strategic Priorities Core Focus Areas Deploy capital to efficiently create meaningful shareholder value Sterile Injectables Bias towards deals with potential for near-t
Slide 4: About Hospira
About Hospira Leading provider of injectable drugs Hospira Composition of Revenues and infusion technologies ~80 years experience, 19,000 employees, Last Twelve Months Revenue = $4,422mm 15 manufacturing plants 13% Specialty Injectable Specialty Injectable Pharmaceuticals (SIP) Pharmaceuticals 19% M
Slide 5: Transaction Overview
Transaction Overview $90.00 per share; 100% cash consideration (financed with mix of cash and debt) Purchase 39% premium to closing price on February 4, 2015 Price Transaction value of approximately $17B (inclusive of net debt) $800 million in annual cost savings expected by 2018 Financial
Slide 6: Transaction combines two highly complementary and synergistic businesses
Transaction combines two highly complementary and synergistic businesses Pfizer Hospira • Leading generics SI company Sterile • Leading off-patent branded SI company • Broad portfolio of SI generic molecules Injectables • InnoPharma transaction brought capability • 1st to market focus to develop har
Slide 7: Generic Sterile Injectables: Large and Growing Segment
Generic Sterile Injectables: Large and Growing Segment SI Generics Marketplace, Gross Sales $70B Generic SI segment expected to grow at 10% vs overall SI at 6% $10 10% $9 Anticipated growth driven by US CAGR (6%), China (13%) and ~$38B Emerging Markets (12%) $7 Growth drivers include generics
Slide 8: Biosimilars: Attractive Growth Opportunity
Biosimilars: Attractive Growth Opportunity >$100B of biologics lose patent protection in next 5-10 years Biosimilars are a potential lever to reduce healthcare costs Development, regulatory, and intellectual property pathways becoming clear Biosimilars Marketplace, Gross Sales $20B $8 $6 $3B $
Slide 9: Key Takeaways
Key Takeaways Acquisition of Hospira will be immediately accretive on closing and will deliver improvement in the growth trajectory of the Global Established Pharma Business and Pfizer overall The transaction aligns with our new commercial structure and is an excellent strategic fit within our G